Survey
Two Week Delay: Survey on Huntington's Disease January 2025
Ticker(s): QURE, PTCT, WVEThe survey results include 20 physicians that manage 3 or more patients with Huntington's Disease.
How many patients with Huntington’s disease do you treat?
Are you knowledgeable about the data for uniQure’s adeno-associated virus gene therapy AMT-130, PTC Therapeutics’ PTC518, and Wave Life Sciences’ WVE-003? Yes/No
What percentage of your Huntington’s disease patients are early stage, middle stage, and late stage?
- Early Stage
- Middle Stage
- Late Stage
What percentage of your Huntington’s disease patients would be able to receive a huntingtin-lowering therapy?
In what percentage of your patients interested in receiving a huntingtin-lowering therapy would you be interested in treating with AMT-130?
What is the reason you would not select a patient to receive AMT-130?
- Safety concerns from surgical procedure
- Complicated logistics from surgical procedure
- Limited efficacy data
- Absence of randomized controlled trial results
- Something else, please specify
In what percentage of your patients interested in receiving a huntingtin-lowering therapy would you be interested in treating with PTC518?
What is the reason you would not select a patient to receive PTC518?
- Safety concerns from prior clinical hold
- Uncertainty on oral drug exposure to the brain
- Limited efficacy data
- Absence of randomized controlled trial results
- Something else, please specify
In what percentage of your patients interested in receiving a huntingtin-lowering therapy would you be interested in treating with WVE-003?
What is the reason you would not select a patient to receive WVE-003?
- Safety concerns from neurofilament light chain changes
- Complicated logistics from chronic intrathecal administration
- Limited efficacy data
- Absence of randomized controlled trial results
- Something else, please specify
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
